Pet Wellness Clinics (Vetscan Imagyst)

Pet Wellness Clinics (Vetscan Imagyst)Pet Wellness Clinics (Vetscan Imagyst)
Pet Wellness Clinics (Vetscan Imagyst)

Pet Wellness Clinics (Vetscan Imagyst)

AI-powered diagnostic solutions for veterinary clinics, including the Vetscan Imagyst analyzer.

DR 492020Active13520
Rate

About

Pet Wellness Clinics (Vetscan Imagyst), part of Zoetis Diagnostics, provides AI-powered veterinary diagnostic solutions. Their core product, the Vetscan Imagyst analyzer, offers seven-in-one diagnostics, including AI-driven analysis for masses, fecal samples, urine sediment, dermatology, blood smears, digital cytology, and equine diagnostics. This platform aims to bring specialist-level medicine and actionable insights to veterinary clinics.
Frequently asked

What does Pet Wellness Clinics (Vetscan Imagyst) do?

Pet Wellness Clinics (Vetscan Imagyst), part of Zoetis Diagnostics, provides AI-powered veterinary diagnostic solutions. Their core product, the Vetscan Imagyst analyzer, offers seven-in-one diagnostics, including AI-driven analysis for masses, fecal samples, urine sediment, dermatology, blood smears, digital cytology, and equine diagnostics. This platform aims to bring specialist-level medicine and actionable insights to veterinary clinics.

What is Pet Wellness Clinics (Vetscan Imagyst)'s revenue?

StartupHub estimates Pet Wellness Clinics (Vetscan Imagyst)'s annual revenue at $2.2B (range $1.4B to $4.2B, 63% confidence), based on comparable companies in the sector.

When was Pet Wellness Clinics (Vetscan Imagyst) founded?

Pet Wellness Clinics (Vetscan Imagyst) was founded in 2020.

What industry does Pet Wellness Clinics (Vetscan Imagyst) operate in?

Pet Wellness Clinics (Vetscan Imagyst) operates in HealthTech, MedTech, Computer Vision, Diagnostics, Veterinary Medicine, Veterinary Diagnostics.

How many employees does Pet Wellness Clinics (Vetscan Imagyst) have?

Pet Wellness Clinics (Vetscan Imagyst) has approximately 13520 people on record.

HEADCOUNT
13520
DOMAIN RATING
49
Comments

No comments yet. Be the first to share your take.